<DOC>
	<DOC>NCT02070978</DOC>
	<brief_summary>This is a multicenter, double-blind, Phase 2b, long-term extension (LTE) to the ADDRESS II core trial (EMR 700461-023) (NCT01972568), to evaluate long-term safety and tolerability of atacicept in subjects with systemic lupus erythematosus (SLE). The Week 24 visit of ADDRESS II core trial will coincide with the Day 1 visit of this LTE trial.</brief_summary>
	<brief_title>Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Patients Who Participated in ADDRESS II)</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus, Systemic</mesh_term>
	<criteria>Subjects who have completed the 24week treatment period of trial EMR700461023 (ADDRESS II core trial) Women of childbearing potential who have a negative pregnancy test Other protocol defined inclusion criteria could apply Active neurological symptoms of SLE that are deemed severe or progressive Diagnosis of any demyelinating disease, such as, but not restricted to, multiple sclerosis (MS) or optic neuritis Pregnancy Active clinically significant viral, bacterial, or fungal infection, or any major episode of infection that in the investigator's opinion makes the subject unsuitable to continue participation in the trial Other protocol defined exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Lupus Erythematosus, Systemic</keyword>
	<keyword>Atacicept 75 and 150 mg</keyword>
	<keyword>LTE</keyword>
</DOC>